Recent evidence suggests that Alzheimer''s disease (AD) may prove to be genetically and aetiologically heterogeneous. Genetic heterogeneity is suggested by linkage of the familial form of the disease to chromosome 21 in some but not all families with early onset and in no families with late onset; and secondly, by the discovery of a mutation in the β-amyloid precursor protein gene on chromosome 21, which is present in only a small minority of early onset families. A role for non-genetic factors is indicated by the high rate of discordance for AD in monozygotic twins. The dementia of boxers which is now reported to be associated with the presence of amorphous amyloid-containing plaques as well as tangles may be the first definite example of non-genetic AD. Case-control studies of AD in which the data have been pooled and re-analysed confirm the importance of genetic factors but also support an independent role for head injury. Apart from the early onset families with autosomal dominant inheritance the pooled data do not suggest that genetic factors are markedly different in the early and late onset cases.

Keywords:
Alzheimer's disease, Genetics, Case-control studies
This content is only available via PDF.
© 1991 S. Karger AG, Basel
1991
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.